Filipe Pereira, PhD

Team

Group Leader

Biography

Filipe Pereira has long held an interest in understanding how cell identity is acquired, maintained and ultimately modified or reversed. During his PhD, he has made his first contributions to the cellular reprogramming field by establishing cell fusion and heterokaryons as a new method to study reprogramming mechanisms towards pluripotency. Then, during his postdoc, he brought cellular reprogramming concepts to hematopoeisis for the first time.

His independent research group has now shown that cooperative transcription factor binding mediates hemogenic induction and pioneered
cell fate reprogramming approaches in immunology with induced dendritic cells. This conceptual shift opens exciting opportunities to merge cellular reprogramming and cancer immunotherapy that his research group will explore during the next years.

The therapeutic potential of these approaches led him to become the co-founder of the spin-off company Asgard Therapeutics AB with support of LU Innovation and LU Holding. Tight collaboration between his research group and Asgard Therapeutics will be critical for translating research findings into new cancer immunotherapies.

Spin-Off Co-Founder

In the Media

_{Filipe’s Publications at Google Scholar}

Academic Background

2019 – Docent in Molecular Medicine at Lund University.
2009 – PhD in Biomedical Sciences. Imperial College School of Medicine, London, U.K.
2002 – Graduation in Biology (4-year degree). Faculty of Sciences, University of Porto, Portugal.

Positions

2019 – Associate Professor and Group Leader. Faculty of Medicine, Lund University, Sweden.
2017 – 2019 Assistant Professor and Group Leader. Faculty of Medicine, Lund University, Sweden.
2015 – Assistant Professor and Group Leader. Center for Neurosciences and Cell Biology (CNC), University of Coimbra, Portugal.
2010 – 2015 Postdoctoral Fellow at Prof. Ihor R. Lemischka and Kateri Moore laboratory. Department of Developmental and Regenerative Biology, Mount Sinai, New York, USA.
2009 – 2010 Postdoctoral Fellow at Prof. Amanda G. Fisher laboratory. MRC Clinical Sciences Centre, Imperial College School of Medicine, London, UK.
2004 – 2009 Graduate Student at Prof. Amanda G. Fisher laboratory. MRC Clinical Sciences Centre, Imperial College School of Medicine, London, UK.
2002 – 2003 Research Assistant at Dr. Fernando Arosa laboratory, Lymphocyte Biology Group. Institute for Cellular and Molecular Cell Biology, Porto University, Porto, Portugal.

Publications

Single-Cell Transcriptional Profiling Informs Efficient Reprogramming of Human Somatic Cells to Cross-Presenting Dendritic Cells

Fábio F. Rosa, Cristiana F. Pires, Ilia Kurochkin, Evelyn Halitzki, Tasnim Zahan, Nejc Arh, Olga Zimmermannová, Alexandra G. Ferreira, Hongzhe Li, Stefan Karlsson, Stefan Scheding, Carlos-Filipe Pereira

March 4, 2022 / Vol. 7, No. 69
Science Immunology

Cell Fate Reprogramming in the Era of Cancer Immunotherapy

Olga Zimmermannova, Inês Caiado, Alexandra G. Ferreira and Carlos-Filipe Pereira

July 21, 2021 / Volume 12, Article 714822
Frontiers in Immunology

Mononuclear Phagocyte Regulation by the Transcription Factor Blimp-1 in Health and Disease

Isabel Ulmert, Luís Henriques‐Oliveira, Carlos‐Filipe Pereira, Katharina Lahl

August 16, 2020
Immunology

Direct Reprogramming of Mouse Embryonic Fibroblasts to Conventional Type 1 Dendritic Cells by Enforced Expression of Transcription Factors

Fábio F. Rosa, Cristiana F. Pires, Olga Zimmermannova and Carlos-Filipe Pereira

May 20, 2020 / Volume 10, Issue 10
Bio-protocol

A SOX2 Reporter System Identifies Gastric Cancer Stem-Like Cells

Diana Pádua, Rita Barros, Ana Luísa Amaral, Patrícia Mesquita, Ana Filipa Freire, Mafalda Sousa, André Filipe Maia, Inês Caiado, Hugo Fernandes, António Pombinho, Carlos Filipe Pereira and Raquel Almeida

February 20, 2020 / Volume 12, Issue 2
Cancers

Is Immunotherapy the Holy Grail for Pancreatic Cancer?

Roland Andersson, Carlos-Filipe Pereira, Monika Bauden, Daniel Ansari

November 21, 2019 / Volume 11, Issue 17
Immunotherapy

Hemogenic Reprogramming of Human Fibroblasts by Enforced Expression of Transcription Factors

Rita Silvério-Alves, Andreia M. Gomes, Ilia Kurochkin, Kateri A. Moore, Carlos-Filipe Pereira

November 4, 2019 / Issue 153
Journal of Visualized Experiments: Jove

Induction of Human Hemogenesis in Adult Fibroblasts by Defined Factors and Hematopoietic Coculture

Michael G. Daniel, David Sachs, Jeffrey M. Bernitz, Yesai Fstkchyan, Katrina Rapp, Namita Satija, Kenneth Law, Foram Patel, Andreia M. Gomes, Huen‐Suk Kim, Carlos‐Filipe Pereira Benjamin Chen, Ihor R. Lemischka, Kateri A. Moore

September 26, 2019 / 593(23):3266-3287
FEBS Letters

Direct Reprogramming of Fibroblasts into Antigen-Presenting Dendritic Cells

Fábio F. Rosa, Cristiana F. Pires, Ilia Kurochkin, Alexandra G. Ferreira, Andreia M. Gomes, Luís G. Palma, Kritika Shaiv, Laura Solanas, Cláudia Azenha, Dmitri Papatsenko, Oliver Schulz, Caetano Reis e Sousa and Carlos-Filipe Pereira

December 7, 2018 / Vol. 3, Issue 30, eaau4292
Science Immunology

Cooperative Transcription Factor Induction Mediates Hemogenic Reprogramming

Andreia M Gomes, Ilia Kurochkin, Betty Chang, Michael Daniel, Kenneth Law, Namita Satija, Alexander Lachmann, Zichen Wang, Lino Ferreira, Avi Ma'ayan, Benjamin K Chen, Dmitri Papatsenko, Ihor R Lemischka, Kateri A Moore, Carlos-Filipe Pereira

December 4, 2018 / Vol. 25, Issue 10
Cell Reports

Compositions for Reprogramming Cells into Dendritic Cells or Antigen Presenting Cells, Methods and Uses Thereof

Fábio F. Rosa, Cristiana F. Pires, Carlos-Filipe Pereira

October 13, 2018
Patent WO-2018-185709

High-throughput Identification of Small Molecules that Affect Human Embryonic Vascular Development

Helena Vazão, Susana Rosa, Tânia Barata, Ricardo Costa, Patrícia R. Pitrez, Inês Honório, Margreet R. de Vries, Dimitri Papatsenko, Rui Benedito, Daniel Saris, Ali Khademhosseini, Paul H. A. Quax, Carlos F. Pereira, Nadia Mercader, Hugo Fernandes, and Lino Ferreira

April 11, 2017 / Volume 114, Issue 15
PNAS

Method for Programming Differentiated Cells into Hematopoietic Stem Cells

Carlos-Filipe Pereira, Kateri A Moore, Ihor R. Lemischka

January 10, 2017
Patent WO-2013-116307

Hematopoietic Reprogramming In Vitro Informs In Vivo Identification of Hemogenic Precursors to Definitive Hematopoietic Stem Cells

Carlos-Filipe Pereira, Betty Chang, Andreia Gomes Jeffrey Bernitz, Dmitri Papatsenko, Xiaohong Niu, Gemma Swiers, Emanuele Azzoni, Marella F.T.R. de Bruijn, Christoph Schaniel, Ihor R. Lemischka, Kateri A. Moore

March 7, 2016 / Volume 36, Issue 5
Developmental Cell

Team